Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282588 | 0.93 | THRB (1.00) | THRBTHRA | |
| SCHEMBL283081 | 0.92 | THRA (1.00) | THRBTHRA | |
| SCHEMBL13381608 | 0.85 | THRB (0.85) | THRBTHRA | |
| SCHEMBL13381659 | 0.84 | THRA (0.84) | THRBTHRA | |
| SCHEMBL21291323 | 0.83 | THRB (0.87) | THRBTHRA | |
| SCHEMBL13121902 | 0.83 | THRB (0.85) | THRBTHRA | |
| SCHEMBL22072255 | 0.83 | THRB (0.77) | THRBTHRA | |
| SCHEMBL18781621 | 0.83 | THRA (0.71) | THRBTHRA | |
| SCHEMBL12825218 | 0.83 | THRA (0.78) | THRBTHRA | |
| SCHEMBL21291313 | 0.82 | THRA (0.77) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | VIKING THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | THRB 7/4885THRA 8/4885 |
| US-11707472-B2 | Compositions for the treatment of fibrosis | COL2A1, TGFBR2, COL1A1 | THRB 33/4885THRA 251/4885 |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | COL2A1, TGFBR2, COL1A1 | THRB 33/4885THRA 251/4885 |
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | TSHR, TPO, THRA | THRB 4/4885THRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.